Alnylam Pharmaceuticals (NASDAQ:ALNY) Receives Neutral Rating from Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their neutral rating on shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a research report report published on Monday, Benzinga reports. They currently have a $150.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also weighed in on the stock. TD Cowen lifted their price target on shares of Alnylam Pharmaceuticals from $260.00 to $282.00 and gave the company a buy rating in a report on Tuesday, June 25th. Barclays lifted their price target on shares of Alnylam Pharmaceuticals from $236.00 to $291.00 and gave the company an overweight rating in a report on Tuesday, June 25th. William Blair reiterated an outperform rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. StockNews.com upgraded shares of Alnylam Pharmaceuticals from a hold rating to a buy rating in a report on Monday, April 29th. Finally, Bank of America lifted their price target on shares of Alnylam Pharmaceuticals from $248.00 to $295.00 and gave the company a buy rating in a report on Tuesday, June 25th. Eight equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of Moderate Buy and an average target price of $249.95.

Alnylam Pharmaceuticals Stock Performance

ALNY stock opened at $248.68 on Monday. The stock has a market capitalization of $31.46 billion, a P/E ratio of -92.79 and a beta of 0.37. Alnylam Pharmaceuticals has a one year low of $141.98 and a one year high of $252.87. The company has a 50 day moving average price of $165.94 and a two-hundred day moving average price of $165.98.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.23. The company had revenue of $494.33 million during the quarter, compared to analyst estimates of $428.01 million. The firm’s revenue for the quarter was up 54.8% compared to the same quarter last year. During the same quarter last year, the business earned ($1.40) EPS. Research analysts forecast that Alnylam Pharmaceuticals will post -3.92 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Yvonne Greenstreet sold 8,301 shares of the business’s stock in a transaction dated Tuesday, June 25th. The shares were sold at an average price of $230.99, for a total value of $1,917,447.99. Following the completion of the sale, the chief executive officer now owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Amy W. Schulman sold 21,700 shares of the business’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $148.60, for a total value of $3,224,620.00. Following the completion of the sale, the director now owns 8,436 shares of the company’s stock, valued at approximately $1,253,589.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Yvonne Greenstreet sold 8,301 shares of the business’s stock in a transaction dated Tuesday, June 25th. The stock was sold at an average price of $230.99, for a total transaction of $1,917,447.99. Following the completion of the sale, the chief executive officer now directly owns 80,534 shares of the company’s stock, valued at approximately $18,602,548.66. The disclosure for this sale can be found here. Insiders have sold 67,357 shares of company stock valued at $13,436,711 in the last quarter. Company insiders own 1.50% of the company’s stock.

Institutional Investors Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently modified their holdings of ALNY. GAMMA Investing LLC grew its position in shares of Alnylam Pharmaceuticals by 97.2% during the 2nd quarter. GAMMA Investing LLC now owns 416 shares of the biopharmaceutical company’s stock valued at $101,000 after buying an additional 205 shares during the last quarter. Teachers Retirement System of The State of Kentucky grew its position in shares of Alnylam Pharmaceuticals by 8.1% during the 1st quarter. Teachers Retirement System of The State of Kentucky now owns 33,213 shares of the biopharmaceutical company’s stock valued at $4,964,000 after buying an additional 2,500 shares during the last quarter. Cetera Advisors LLC bought a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $238,000. Burney Co. grew its position in shares of Alnylam Pharmaceuticals by 371.9% during the 1st quarter. Burney Co. now owns 27,059 shares of the biopharmaceutical company’s stock valued at $4,044,000 after buying an additional 21,325 shares during the last quarter. Finally, Swedbank AB bought a new stake in shares of Alnylam Pharmaceuticals during the 1st quarter valued at about $3,084,000. Institutional investors own 92.97% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.